Scroll Top
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles

Home » Newsroom

Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
By Admin Roshan

06 Oct: Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® 

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and …

Read more

Read More
By

23 Sep: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

18 Sep: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing …

Read more

Read More
By Admin Roshan

04 Sep: Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The …

Read more

Read More
By Admin Roshan

12 Aug: Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis …

Read more

Read More
By

24 Jul: Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

16 Jul: Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

15 Jul: Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

30 Jun: Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q …

Read more

Read More
By

10 Jun: Gain Therapeutics to Participate in Upcoming Investor Conferences

BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

29 May: Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

14 May: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. …

Read more

Read More
By

12 May: Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity BETHESDA, Md., …

Read more

Read More
By

01 May: Gain Therapeutics to Participate at The Citizens Life Sciences Conference

BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

30 Apr: Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

10 Apr: Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b …

Read more

Read More
By

28 Mar: Gain Therapeutics Announces Poster Presentation at AD/PD 2025

BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

27 Mar: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, …

Read more

Read More
By

14 Mar: Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

Interim Analysis Expected End of 2Q 2025 BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a …

Read more

Read More
By

06 Mar: Gain Therapeutics Announces Oral Presentation at AD/PD 2025

BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

06 Feb: Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

05 Feb: Gain Therapeutics To Participate in Upcoming Investor Conferences

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By

08 Jan: Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

07 Jan: Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, …

Read more

Read More
By

23 Dec: Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability …

Read more

Read More
By

11 Dec: Gain Therapeutics To Present At Biotech Showcase 2025

Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) …

Read more

Read More
By

14 Nov: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024 BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, …

Read more

Read More
By Admin Roshan

23 Oct: Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology …

Read more

Read More
By Admin Roshan

15 Oct: Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

09 Oct: Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
1 2 … 6
About Us
  • Overview
  • Leadership Team
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
Science & Technology
  • Platform Technology
  • Science
  • Posters
  • Publications
INVESTORS & MEDIA
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Investor Resources
  • SEC Filings
  • Governance Documents
  • 2024 Gain Therapeutics, Inc.
Linkedin-in Twitter Youtube
  • ©2023 Gain Therapeutics, Inc.
  • Pipeline
  • Perspectives
  • Contact Us
  • Sign up
Linkedin-in Twitter Youtube
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles